StocksMediumUpdated•Originally published 12 November 2026•Updated 12 November 2026•
1 min read
Twist Bioscience Q4 Revenue Jumps 27.9% as Company Issues Strong 2027 Guidance
Key Facts
1Twist Bioscience announced financial results for its fiscal fourth quarter and full year ended September 30, 2026.
Twist Bioscience reported revenue of $126.6 million for the fourth quarter ended September 30, 2026, marking a 27.9% increase year-over-year. The company also issued revenue guidance for fiscal year 2027, projecting a range between $550 million and $560 million.
TWST closed at $122.59 on November 11, 2026, having reached a session high of $151.5 and a low of $122.08. The financial results, released via Business Wire, highlighted an outperformance in earnings per share alongside the significant revenue growth.